Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Comment by narmacon Aug 25, 2021 9:27am
691 Views
Post# 33760361

RE:RE:RE:RE:RE:.52 cents coming,,possibly lower me thinks.

RE:RE:RE:RE:RE:.52 cents coming,,possibly lower me thinks.,,,well,,,insiders certainly could have a different agenda to what retail shareholders expect! I will assume we agree on that point. Our future depends on the insiders strategy imo. I doubt it that flipping shares is their end game!!!!! So complete failure by managment may be what they are hoping for.!!,Lebioda might have been muffled to ensure the share price is kept artificially low. The lack of business deveopment might support that theory. He had the ewxperience to make a difference but it never materialized in the bisiness sense.I am leaning more on the take over of this company by Hepa. DMcC is a puppet me thinks and being a symposium planner adds to the incompetence of moving forward at any speed if he actually does have any authority within.
<< Previous
Bullboard Posts
Next >>